Compare MGNX & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGNX | AUDC |
|---|---|---|
| Founded | 2000 | 1992 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.4M | 247.7M |
| IPO Year | 2013 | 2000 |
| Metric | MGNX | AUDC |
|---|---|---|
| Price | $1.97 | $8.56 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 115.0K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 4.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | $3.05 |
| Revenue Next Year | N/A | $3.87 |
| P/E Ratio | ★ N/A | $23.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $6.95 |
| 52 Week High | $5.08 | $11.74 |
| Indicator | MGNX | AUDC |
|---|---|---|
| Relative Strength Index (RSI) | 26.92 | 36.29 |
| Support Level | $1.93 | $8.27 |
| Resistance Level | $3.39 | $9.17 |
| Average True Range (ATR) | 0.18 | 0.49 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 11.86 | 34.19 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).